间充质干细胞
CD90型
细胞疗法
多能干细胞
干细胞
川地34
医学
细胞生物学
生物
祖细胞
作者
Massimo Dominici,Katarina Le Blanc,Ingo Mueller,Ineke Slaper‐Cortenbach,F. Marini,Diane S. Krause,R. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz
出处
期刊:Cytotherapy
[Elsevier]
日期:2006-01-01
卷期号:8 (4): 315-317
被引量:15827
标识
DOI:10.1080/14653240600855905
摘要
The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
科研通智能强力驱动
Strongly Powered by AbleSci AI